Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000295174 is a long non-coding RNA (lncRNA) gene, transcribed in the antisense direction relative to the protein-coding TTC27 (Tetratricopeptide repeat domain 27) gene[3]. As an antisense lncRNA, it may participate in the regulation of TTC27 via mechanisms typical of antisense transcripts, such as RNA interference, modulation of chromatin structure, transcriptional interference, or influence on mRNA stability[1][5]. However, there is currently no experimental evidence describing the specific function, disease implication, or drug interaction profile for this lncRNA. It is not classified as a receptor, enzyme, transporter, or recognized therapeutic target. It does, however, fall within the general molecular classification of "long non-coding RNA" with potential regulatory roles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to TTC27 (ENSG00000295174).